SOUTH SAN FRANCISCO, Calif., Oct. 31, 2006 (PRIMEZONE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced the initiation of a multicenter Phase II clinical trial with Talvesta(tm) (talotrexin) for Injection in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
